Celcuity Inc (NASDAQ:CELC) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 66,200 shares, a decline of 38.0% from the May 15th total of 106,800 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average daily volume of 5,500 shares, the short-interest ratio is currently 12.0 days.
Several hedge funds have recently modified their holdings of CELC. BNP Paribas Arbitrage SA grew its position in shares of Celcuity by 13,655.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,238 shares of the company’s stock valued at $27,000 after acquiring an additional 1,229 shares during the period. Nelson Roberts Investment Advisors LLC bought a new position in Celcuity in the 1st quarter worth $115,000. Kessler Investment Group LLC boosted its holdings in Celcuity by 46.3% in the 1st quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock worth $154,000 after buying an additional 2,222 shares during the period. Bank of New York Mellon Corp boosted its holdings in Celcuity by 32.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 15,483 shares of the company’s stock worth $445,000 after buying an additional 3,761 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Celcuity by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock worth $840,000 after buying an additional 2,930 shares during the period. 22.05% of the stock is owned by hedge funds and other institutional investors.
Shares of CELC stock traded down $0.34 during mid-day trading on Friday, reaching $21.41. 571 shares of the company’s stock traded hands, compared to its average volume of 6,780. Celcuity has a 12 month low of $18.31 and a 12 month high of $31.00. The firm’s 50 day moving average price is $21.80. The company has a quick ratio of 26.94, a current ratio of 26.94 and a debt-to-equity ratio of 0.01. The stock has a market cap of $222.07 million, a price-to-earnings ratio of -28.93 and a beta of 0.38.
CELC has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Celcuity from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Thursday, February 28th. ValuEngine raised shares of Celcuity from a “hold” rating to a “buy” rating in a research report on Friday, March 15th. Finally, HC Wainwright set a $36.00 price objective on shares of Celcuity and gave the company a “buy” rating in a research report on Wednesday, May 8th.
Celcuity Company Profile
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Recommended Story: What is the formula for the cash asset ratio?
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.